In a study reported in Journal of Clinical Oncology, Shukui Qin, MD, of People’s Liberation Army Cancer Centre, Bayi Hospital, in Nanjing, and colleagues compared FOLFOX4 (infusional fluorouracil [5-FU], leucovorin, and oxaliplatin) with doxorubicin as palliative chemotherapy in patients with ...
The investigational agent brivanib is a selective dual inhibitor of VEGF and fibroblast growth factor receptors, both implicated in hepatocellular carcinoma. In a trial (BRISK-PS) reported in Journal of Clinical Oncology, Josep M. Llovet, MD, of the Icahn School of Medicine at Mount Sinai in New...
The investigational drug brivanib is a dual inhibitor of VEGF and fibroblast growth factor signaling, both implicated in hepatocellular carcinoma. In a noninferiority trial (BRISK-FL) reported in Journal of Clinical Oncology, Philip J. Johnson, MD, of the Institute of Translational Medicine,...